Patents matching “anti-”

US 10611816

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10610486

Sustained release formulation of a non-steroidal anti-inflammatory drug

Pacira Pharmaceuticals, Inc. · Granted Apr 7, 2020 · Expires Apr 2, 2040

US 10604582

Anti-CD276 antibodies (B7H3)

The United States of America, as represented by the Secretary, Department of Health · Granted Mar 31, 2020 · Expires Mar 26, 2040

US 10596270

Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

Sutro Biopharma, Inc. · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10596304

Anti-infective functionalized surfaces and methods of making same

THE TRUSTEES OF PRINCETON UNIVERSITY · Granted Mar 24, 2020 · Expires Mar 19, 2040

US 10568877

Preparation and anti-HSV-1 application of quinolinone derivatives

OCEAN UNIVERSITY OF CHINA · Granted Feb 25, 2020 · Expires Feb 20, 2040

US 10570214

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 25, 2020 · Expires Feb 20, 2040

US 10562952

Anti-CD276 chimeric antigen receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 18, 2020 · Expires Feb 13, 2040

US 10562886

Anti-cancer compounds

The Regents of the University of California · Granted Feb 18, 2020 · Expires Feb 13, 2040

US 10557850

Anti-CXCR1 compositions and methods

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 11, 2020 · Expires Feb 6, 2040

US 10556875

Bis-diazeniumdiolate compounds as anti-cancer agents

ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Feb 11, 2020 · Expires Feb 6, 2040

US 2020040086

PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-LY75 ANTIBODY

BERLIN CHEMIE AG [DE] · Granted Feb 6, 2020 · Expires Feb 1, 2040

US 10544223

Combination therapy with an anti-axl antibody-drug conjugate

ADC THERAPEUTICS SA · Granted Jan 28, 2020 · Expires Jan 23, 2040

US 10544232

Methods for treating patients with heterozygous familial hypercholesterolemia (heFH) with an anti-PCSK9 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Jan 28, 2020 · Expires Jan 23, 2040

US 10537537

Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

INSTITUT PASTEUR DE MONTEVIDEO · Granted Jan 21, 2020 · Expires Jan 16, 2040

US 10532096

Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody

REGENERON PHARMACEUTICALS, INC. · Granted Jan 14, 2020 · Expires Jan 9, 2040

US 10533056

Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics

The Regents of the University of California · Granted Jan 14, 2020 · Expires Jan 9, 2040

US 10525068

Anti-inflammatory properties of marine lipid compositions

AKER BIOMARINE ANTARCTIC AS · Granted Jan 7, 2020 · Expires Jan 2, 2040

US 10526414

Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

VACCINEX, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

US 10526403

Anti-activin A antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

US 10525104

Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

US 10517948

Anti-DC-HIL antibodies for cancer diagnosis, prognosis and therapy

The Board of Regents of the University of Texas System · Granted Dec 31, 2019 · Expires Dec 26, 2039

US 10519240

Anti-FGFR1c antibody-FGF21 fusion proteins

REGENERON PHARMACEUTICALS, INC. · Granted Dec 31, 2019 · Expires Dec 26, 2039

US 10513558

Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof

CytomX Therapeutics, Inc. · Granted Dec 24, 2019 · Expires Dec 19, 2039